Effectiveness of edaravone in preventing contrast‐induced nephropathy in high‐risk patients undergoing coronary angiography: A randomized, double‐blind trial
Pharmacology Research & Perspectives · 2024
DOI: 10.1002/prp2.1228 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Pharmacology Research & Perspectives, 2024. Verfasst von Azam Esmailnejad und 9 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. Hauptthemen laut MEDLINE: Edaravone, Contrast Media, Coronary Angiography. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tabriz University of Medical Sciences.
Abstract (Originalsprache)
Contrast‐induced nephropathy (CIN) is a serious complication that occurs subsequent to the administration of contrast media for therapeutic angiographic interventions. As of present, no effective therapy exists to prevent its occurrence. This single‐center double‐blind randomized controlled trial aimed to evaluate the effect of edaravone, an antioxidant, in a group of high‐risk patients undergoing coronary angiography. Ninety eligible patients with chronic kidney disease Stages 3–4 were randomly assigned to either the control group ( n = 45) or the intervention group ( n = 45). In the intervention group, one dosage of edaravone (60 mg) in 1 L of normal saline was infused via a peripheral vein 1 h prior to femoral artery‐directed coronary angiography. Patients in the control group received an equal amount of infusion in their last hour before angiography. Both groups received intravenous hydration with 0.9% sodium 1 mL/kg/h starting 12 h before and continuing for 24 h after angiography. The primary outcome measure was the onset of CIN, defined as a 25% increase in serum creatinine levels 120 h after administration of contrast media. The occurrence of CIN was observed in 5.5% ( n = 5) of the studied population: 2.2% of patients in the intervention group ( n = 1) and 8.9% of controls ( n = 4). However, this difference was not statistically significant. Administration of a single dosage of edaravone 1 h prior to infusion of contrast media led to a reduction in the incidence of CIN. Further investigations, employing larger sample sizes, are warranted to gain a comprehensive understanding of its efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
- Kidney Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
- School of Pharmacy and Pharmaceutical Sciences, Islamic Azad University, Teheran, Iran.
ORCID-Profile: Azam Esmailnejad, Sepideh Zununi Vahed, Seyyedeh Mina Hejazian, Naser Aslanabadi, Mohammadreza Ardalan, Samad Ghaffari Bavil
Förderung
- Tabriz University of Medical Sciences
Zitieren
APA
Esmailnejad, A., Zununi Vahed, S., Hejazian, S. M., Aslanabadi, N., Lotfollahhi Gharakhanlu, H., Saraei, M., Ahmadzadehpournaky, A., Ardalan, K., Ardalan, M., & Ghaffari Bavil, S. (2024). Effectiveness of edaravone in preventing contrast‐induced nephropathy in high‐risk patients undergoing coronary angiography: A randomized, double‐blind trial. Pharmacology Research & Perspectives. https://doi.org/10.1002/prp2.1228
Vancouver
Esmailnejad A, Zununi Vahed S, Hejazian SM, Aslanabadi N, Lotfollahhi Gharakhanlu H, Saraei M, et al. Effectiveness of edaravone in preventing contrast‐induced nephropathy in high‐risk patients undergoing coronary angiography: A randomized, double‐blind trial. Pharmacology Research & Perspectives. 2024. doi:10.1002/prp2.1228
BibTeX
@article{Esmailnejad2024,
author = {Esmailnejad, Azam and Zununi Vahed, Sepideh and Hejazian, Seyyedeh Mina and Aslanabadi, Naser and Lotfollahhi Gharakhanlu, Hassanali and Saraei, Majid and Ahmadzadehpournaky, Ahmad and Ardalan, Kasra and Ardalan, Mohammadreza and Ghaffari Bavil, Samad},
title = {Effectiveness of edaravone in preventing contrast‐induced nephropathy in high‐risk patients undergoing coronary angiography: A randomized, double‐blind trial},
journal = {Pharmacology Research & Perspectives},
year = {2024},
doi = {10.1002/prp2.1228}
}
EUVIMED